CRMD — CorMedix Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1410098 ·
Last close
$4.67
Market Cap
$371.44M
52W High
$13.02
52W Low
$4.64
ADV30
1,856,642
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 51,264,000 | 26,749,000 | -6,619,000 | -14,722,000 | 917,745,000 | 355,150,000 | 456,039,000 |
| Jun 2026 | 99,307,000 | 74,502,000 | 42,910,000 | 25,988,000 | 904,052,000 | 256,692,000 | 443,219,000 |
| Mar 2026 | 127,427,000 | 105,122,000 | 63,658,000 | 38,601,000 | 815,637,000 | 178,087,000 | 378,588,000 |
| Dec 2025 | 128,615,264 | 107,308,042 | 59,126,248 | 14,020,141 | 826,142,000 | 144,837,000 | 420,835,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$312,779,181
Investing CF
$3,788,039
Financing CF
$-9,909,058
CapEx
$-4,923,104
Dividends Paid
—
Buybacks
$-17,484,000
EPS Diluted TTM
$0.69
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-126,708,000
Inventory
$43,144,000
Receivables
$76,706,000
ST Investments
$0
EBIT TTM
$158,212,515
Pretax Income TTM
$134,376,436
Interest Exp TTM
$2,781,999
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$412,492,000
EBITDA
$211,322,000
Free Cash Flow
$288,815,392
Enterprise Value
$162,955,344
Total Cash
$355,150,016
Total Debt
$147,460,000
Shares Out
79,537,626
Trailing EPS
$1.97
Book Value
$5.81
ROE
15.3%
ROA
12.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 311,709,000 | 150,141,000 | 163,055,000 | 826,142,000 | 420,835,000 | 405,307,000 | 175,046,000 |
| Dec 2024 | 43,472,000 | -22,356,000 | -17,930,000 | 118,846,000 | 34,189,000 | 84,657,000 | -50,615,000 |
| Dec 2023 | 0 | -48,957,788 | -46,339,227 | 82,059,957 | 11,917,528 | 70,142,429 | -38,409,480 |
| Dec 2022 | 65,408 | -30,623,968 | -29,701,705 | 62,038,259 | 6,978,523 | 55,059,736 | -24,356,732 |
TTM Snapshot
Revenues TTM
$462,248,553
NetIncome TTM
$187,172,121
OpCashFlow TTM
—
Assets (Latest)
$904,052,000
Forward EPS
$0.35
Max Pain — expiry 2027-01-15
max pain strike: $3.00 · spot: $4.50 · call oi: 0 · put oi: 1,008Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NIKA | NIKA PHARMACEUTICALS, INC | $369.14M | $0.35 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $369.13M | $7.14 | — |
| SPRY | ARS Pharmaceuticals, Inc. | $366.93M | $3.65 | — |
| CYDY | CytoDyn Inc. | $366.64M | $0.25 | — |
| PEPG | PepGen Inc. | $365.73M | $3.88 | — |
News headlines (Yahoo Finance, 1h cache)
CorMedix's DefenCath, Rezzayo to Drive 2027 Growth, Oppenheimer Says
2026-11-13 17:07 · Yahoo
CorMedix Inc. Q3 2026 Earnings Call Summary
2026-11-12 18:03 · Yahoo
CorMedix (CRMD) Q3 2026 Earnings Call Transcript
2026-11-12 18:00 · Yahoo
What CorMedix (CRMD) Said on Its Q3 Earnings Call
2026-11-12 17:15 · Yahoo
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
2026-11-12 12:50 · Yahoo
CorMedix: Q3 Earnings Snapshot
2026-11-12 12:43 · Yahoo
CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
2026-11-10 13:17 · Yahoo
CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings
2026-11-10 11:12 · Yahoo
CorMedix stock gains as Heron deal adds four products
2026-11-09 13:59 · Yahoo
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
2026-11-09 12:15 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-18 17:21:30 | 2026-11-16 | Kaplan Myron | Dir | P - Purchase | 4.88 | 25000 | 122000 |